title: Etrolizumab for ulcerative colitis: the new kid on the block?
abstract: BACKGROUND
  Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown etiology. Currently approved therapies include prednisone, TNF antagonists and anti-metabolites which often are ineffective and have frequent adverse effects. Consequently, UC patients are always at risk for developing serious complications that affect their quality of life. Therefore, new treatment options are required.
  
  
  METHODS
  This article discusses etrolizumab, its mechanism and the potential role it can have in the future of treating UC. Etrolizumab is a humanized monoclonal antibody that selectively blocks lymphocyte trafficking and retention in the gut. The safety and efficacy data was reviewed from all randomized placebo-controlled trials which evaluated etrolizumab for the treatment of UC.
  
  
  CONCLUSIONS
  Etrolizumab is an effective and well-tolerated drug for the treatment of UC. It appears to be a promising molecule that can benefit UC patients.
authors.affiliation: a Division of Digestive Disease , University of California Los Angeles , Los Angeles , CA , USA.
authors.forename: Jitin
authors.initials: J
authors.lastname: Makker
authors.affiliation: a Division of Digestive Disease , University of California Los Angeles , Los Angeles , CA , USA.
authors.forename: Daniel W
authors.initials: DW
authors.lastname: Hommes
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D006801:Humans; D011788:Quality of Life; D016201:Receptors, Lymphocyte Homing
chemical_list: D000897:Anti-Ulcer Agents; D061067:Antibodies, Monoclonal, Humanized; D016201:Receptors, Lymphocyte Homing; C559198:etrolizumab
keywords: Anti-integrins; etrolizumab; ulcerative colitis